AstraZeneca Inks R&D Deal With Ramaswamy's Roivant for Hush-Hush Indication Post author:Sam Post published:October 18, 2017 Post category:BioPharma Vivek Ramaswamy’s parent company, Roivant Sciences, inked a development deal with Astra. Source: BioSpace You Might Also Like Charles River Slams Down $800M Cash for Global CRO February 12, 2018 FDA Calls BioMarin's Hemophilia A Drug a Breakthrough October 25, 2017 FDA Grants New Clearance for NICO Corporation's Brain Surgery Technology January 31, 2017
